Final Program

344 WEDNESDAY • MAY 18
10:15 Plasma Metabolomics Analysis Identifies Candidate
Biomarkers of Flavoring-Induced Bronchiolitis Obliterans/M.W.
Foster, J.W. Thompson, D.M. Brass, M.A. Moseley, D.L. Morgan,
S.M. Palmer, Durham, NC, p.A6452
10:30 Metabolomic Profiling of Childhood Asthma Severity in a
Costa-Rican Population: Insights into Disease
Pathogenesis/R.S. Kelly, A. Dahlin, A.C. Wu, M. McGeachie, D.C.
Croteau-Chonka, S.T. Weiss, J. Lasky-Su, Boston, MA, p.A6453
10:45 Varying Effects of PM2.5, Genetic and Epigenetic Variations in
iNOS Promoter on FeNO in Children/Y. Zhang, M. Salam, K.
Berhane, S. Eckel, E. Rappaport, W. Linn, R. Habre, T. Bastain, F.
Gilliland, Salt Lake City, UT, p.A6454
D18
MINI SYMPOSIUM
CYSTIC FIBROSIS AND PRIMARY CILIARY
DYSKINESIA: TWO SIDES OF THE SAME COIN?
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Chairing: A.J. Shapiro, MD, Montreal, Canada
D. Hayes, MD, Columbus, OH
Oral Presentations
Room 3007/3009 (West Building, Level 3)
9:00 Respiratory Microbiology in Primary Ciliary Dyskinesia:
Comparisons to a Pediatric Cystic Fibrosis Cohort/M.C. Tracy,
J.M. Zirbes, C. Hernandez, D.N. Cornfield, C.E. Milla, Palo Alto,
CA, p.A6455
9:15 Comparison of the Microbiota of the Airway in Children with
Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis/R.J.
Green, S. Vosloo, R. Masekela, S. De Beer, F. Venter, Pretoria,
South Africa, p.A6456
9:30 A Comparison of Anaerobic to Aerobic Power Ratio in Children
with Primary Ciliary Dyskinesia and Healthy Controls/S.
Simsek, D. Inal-Ince, A. Cakmak, E. Calik-Kutukcu, M. Saglam, N.
Vardar-Yagli, N. Emiralioglu, H.U. Ozcelik, H. Sonbahar-Ulu, C.
Bozdemir-Ozel, H. Arikan, N. Kiper, Ankara, Turkey, p.A6457
9:45 In Vivo Cystic Fibrosis (CF) Nasal Epithelial Transcriptomic
Studies Reveal non-CFTR Differential Gene Expression
Associated with CF Lung Disease Severity/D. Polineni, H. Dang,
R.G. Pace, J.R. Stonebraker, X.G. Guo, L.C. Jones, C.R. Esther,
M.P. Boyle, J.F. Chmiel, P.R. Durie, P.J. Gallins, F.A. Wright, W.K.
O’Neal, M. Knowles, Kansas City, KS, p.A6458
10:00 The Influence of Secondhand Smoke Exposure on Arachidonic
Acid Metabolism and Outcomes in Infants and Young Children
with Cystic Fibrosis/B.T. Kopp, L.K. Rogers, A. Mejias, D. Hayes,
Jr., D. Tumin, F. Woodley, R. Thompson, J. Groner, Columbus,
OH, p.A6459
10:15 Minorities with Cystic Fibrosis Are Underrepresented in
Pharmacology Clinical Trials/M.E. McGarry, S.A. McColley, San
Francisco, CA, p.A6460
10:30 Age-Related Survival Disparity Associated with Lung
Transplantation in Cystic Fibrosis: An International Study/
D. Hayes, Jr., A.R. Glanville, D. McGiffin, J.D. Tobias, D. Tumin,
Columbus, OH, p.A6461
Featured Speaker
10:45 Contrasting the CF and PCD Phenotypes/S.D. Davis, MD,
Indianapolis, IN,
D19
MINI SYMPOSIUM
CLINICAL STUDIES IN PH
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Chairing: R.T. Zamanian, MD, Stanford, CA
R. Souza, MD, PhD, Sao Paulo, Brazil
I. Lang, MD, Vienna, Austria
Oral Presentations
Room 3010/3012 (West Building, Level 3)
9:00 Comprehensive Characterization of Insulin Resistance and Its
Association with Ventricular Function in Pulmonary Arterial
Hypertension/R.E. Wells, M. Cuttica, R. Dash, F. Abbasi, M. Van
De Veerdonk, I.R. Preston, A.R. Hemnes, A.J. Sweatt, M.
Gomberg-Maitland, R.T. Zamanian, Stanford, CA, p.A6462
9:15 Sarcoidosis-Associated Pulmonary Hypertension in the Modern
PAH-Targeted Therapy Era: Experience from the French
Registry/A. Boucly, H. Nunes, X. Jais, V. Cottin, A. Tazi, O. Sanchez,
G. Prevot, M. Reynaud Gaubert, C. Dromer, C. Viacroze, D. Horeau
Langlard, C. Pison, E. Bergot, D. Montani, G. Simonneau, M. Humbert,
O. Sitbon, L. Savale, Le Kremlin Bicêtre, France, p.A6463
9:30 Serial Vasoreactivity Reassessment Is a Prognostic Tool in
Pulmonary Arterial Hypertension/A.J. Sweatt, E.F.
Spiekerkoetter, A. Hsi, Y. Sung, V. De Jesus Perez, K. Kudelko,
R.T. Zamanian, Stanford, CA, p.A6464
9:45 Extended Evaluation of emPHasis-10 Quality of Life
Questionnaire in PH/I. Smith, C. Billings, D. Kiely, J. Yorke, I.
Armstrong, Sheffield, United Kingdom, p.A6465
10:00 Targeting the Prostacyclin Pathway in the Treatment of
Connective Tissue Disease Associated Pulmonary Arterial
Hypertension (PAH): Insights from the Randomized Controlled
GRIPHON Trial with Selexipag/S.P. Gaine, R.N. Channick, L. Di
Scala, N. Galie, H.-A. Ghofrani, M.M. Hoeper, I. Lang, V.
McLaughlin, R. Preiss, L.J. Rubin, G. Simonneau, O. Sitbon, V.
Tapson, K.M. Chin, Dublin, Ireland, p.A6466
10:15 Comparative Effectiveness of Pharmacological Interventions for
Pulmonary Arterial Hypertension: A Systematic Review and
Network Meta-Analysis/S. Jain, R. Khera, Z. Wang, M.H. Murad, A.
Blevins, G.A. Schmidt, S. Singh, A.K. Gerke, Iowa City, IA, p.A6467
10:30 A Randomized Open Label Study Comparing First-Line
Treatment with Bosentan or Sildenafil in Chronic
Thromboembolic Pulmonary Hypertension/E. Gotti, M. Palazzini,
A. Manes, C. Bachetti, G. Mazzanti, A. Rinaldi, F. Dardi, A. Albini, E.
Monti, S. Fukui, D. Guarino, N. Galie, Bologna, Italy, p.A6468
ATS 2016 • San Francisco